摘要
目的:研究胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱的临床效果。方法:选取2016年1月-2018年6月于本院接受治疗的多囊卵巢综合征内分泌紊乱患者90例,按随机数字表法分为观察组与对照组,各45例。观察组采取常规治疗联合胰岛素增敏剂,对照组实施常规治疗。比较两组治疗效果、治疗后雌激素、胰岛素及血糖水平。结果:观察组治疗总有效率为95.56%明显高于对照组的80.00%(P<0.05)。治疗后观察组黄体生成激素、睾酮、硫酸脱氢表雄酮、雄烯二酮、雌二醇、性激素结合球蛋白、卵泡生成激素、Homa-β功能指数、空腹血糖、胰岛素抵抗指数及空腹胰岛素均优于对照组(P<0.05)。结论:常规治疗联合胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱效果显著,能够快速改善患者性激素水平、胰岛素水平和血糖水平,促进患者临床症状的缓解,提升治疗效率,具有较高的临床应用价值。
Objective:To study the clinical effect of insulin sensitizer in the treatment of endocrine disorders in polycystic ovary syndrome.Method:A total of 90 patients with endocrine disorders with polycystic ovary syndrome received treatment in our hospital from January 2016 to June 2018 were selected.According to the random number table method,they were divided into observation group and control group,with 45 cases in each group.The observation group was treated with routine treatment combined with insulin sensitizer,while the control group was treated with routine treatment.The therapeutic effect,estrogen,insulin and blood glucose levels after treatment were compared between the two groups.Result:The total effective rate of the observation group was 95.56%significantly higher than 80.00%of the control group(P<0.05).After treatment,luteinizing hormone,testosterone,dehydroepiandrosterone sulfate,androstenedione sulfate,estradiol,sex hormone binding globulin,follicular follicular hormone,Homa-βfunction index,fasting blood glucose,insulin resistance index and fasting insulin in the observation group were all better than those in the control group(P<0.05).Conclusion:Conventional therapy combined with insulin sensitizer has significant effect on endocrine disorders of polycystic ovary syndrome.It can promote the rapid improvement of sex hormone level,insulin level and blood sugar level,promote the rapid relief of clinical symptoms,and improve the treatment efficiency of patients.It has high clinical application value.
作者
崔晓洁
CUI Xiaojie(Fujian Province Xiamen No.5 Hospital,Xiamen 361101,China)
出处
《中国医学创新》
CAS
2019年第28期142-145,共4页
Medical Innovation of China
